Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM (aflibercept 2 mg) with fixed intervals of 8 weeks...

Get In Touch

123 Street, New York, USA

+012 345 67890

Follow Us
Flickr Photos

Copyright © 2023 All Rights Reserved